XML 51 R32.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Segments of Business and Geographic Areas (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2024
Segment Reporting [Abstract] |
Sales By Segment Of Business |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $2,453 |  | 2,448 |  | 0.2 | % |  |  |  |  |  |
International |  | 1,794 |  | 1,664 |  | 7.9 |  |  |  |  |  |  |
Worldwide |  | 4,247 |  | 4,112 |  | 3.3 |  |  |  |  |  |  |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 266 |  | 276 |  | (3.9) |  |  |  |  |  |  |
U.S. Exports |  | 27 |  | 41 |  | (32.7) |  |  |  |  |  |  |
International |  | 141 |  | 170 |  | (17.2) |  |  |  |  |  |  |
Worldwide |  | 434 |  | 487 |  | (10.9) |  |  |  |  |  |  |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 254 |  | 271 |  | (6.2) |  |  |  |  |  |  |
International |  | 299 |  | 266 |  | 12.4 |  |  |  |  |  |  |
Worldwide |  | 554 |  | 537 |  | 3.0 |  |  |  |  |  |  |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,396 |  | 1,451 |  | (3.8) |  |  |  |  |  |  |
International |  | 1,055 |  | 993 |  | 6.2 |  |  |  |  |  |  |
Worldwide |  | 2,451 |  | 2,444 |  | 0.3 |  |  |  |  |  |  |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 509 |  | 406 |  | 25.4 |  |  |  |  |  |  |
International |  | 299 |  | 234 |  | 27.9 |  |  |  |  |  |  |
Worldwide |  | 808 |  | 640 |  | 26.3 |  |  |  |  |  |  |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 3 |  | * |  |  |  |  |  |
International |  | 0 |  | 0 |  | — |  |  |  |  |  |  |
Worldwide |  | 0 |  | 3 |  | * |  |  |  |  |  |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 324 |  | 392 |  | (17.4) |  |  |  |  |  |  |
International |  | 497 |  | 1,193 |  | (58.4) |  |  |  |  |  |  |
Worldwide |  | 821 |  | 1,586 |  | (48.3) |  |  |  |  |  |  |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 0 |  | — |  |  |  |  |  |  |
International |  | 25 |  | 747 |  | (96.6) |  |  |  |  |  |  |
Worldwide |  | 25 |  | 747 |  | (96.6) |  |  |  |  |  |  |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 8 |  | 9 |  | (10.9) |  |  |  |  |  |  |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
International |  | 315 |  | 271 |  | 16.6 |  |  |  |  |  |  |
Worldwide |  | 323 |  | 280 |  | 15.7 |  |  |  |  |  |  |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 314 |  | 378 |  | (16.9) |  |  |  |  |  |  |
International |  | 104 |  | 99 |  | 5.5 |  |  |  |  |  |  |
Worldwide |  | 418 |  | 477 |  | (12.3) |  |  |  |  |  |  |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2 |  | 5 |  | (68.8) |  |  |  |  |  |  |
International |  | 52 |  | 77 |  | (32.8) |  |  |  |  |  |  |
Worldwide |  | 53 |  | 82 |  | (35.1) |  |  |  |  |  |  |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,054 |  | 978 |  | 7.8 |  |  |  |  |  |  |
International |  | 749 |  | 826 |  | (9.3) |  |  |  |  |  |  |
Worldwide |  | 1,803 |  | 1,804 |  | 0.0 |  |  |  |  |  |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 41 |  | 70 |  | (41.2) |  |  |  |  |  |  |
International |  | 136 |  | 136 |  | (0.1) |  |  |  |  |  |  |
Worldwide |  | 177 |  | 206 |  | (14.1) |  |  |  |  |  |  |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 765 |  | 713 |  | 7.2 |  |  |  |  |  |  |
International |  | 292 |  | 331 |  | (11.8) |  |  |  |  |  |  |
Worldwide |  | 1,056 |  | 1,044 |  | 1.2 |  |  |  |  |  |  |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 191 |  | 111 |  | 71.5 |  |  |  |  |  |  |
International |  | 34 |  | 20 |  | 76.1 |  |  |  |  |  |  |
Worldwide |  | 225 |  | 131 |  | 72.2 |  |  |  |  |  |  |
OTHER NEUROSCIENCE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 58 |  | 84 |  | (31.1) |  |  |  |  |  |  |
International |  | 287 |  | 339 |  | (15.5) |  |  |  |  |  |  |
Worldwide |  | 345 |  | 423 |  | (18.5) |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,383 |  | 1,889 |  | 26.2 |  |  |  |  |  |  |
International |  | 2,430 |  | 2,223 |  | 9.3 |  |  |  |  |  |  |
Worldwide |  | 4,814 |  | 4,112 |  | 17.1 |  |  |  |  |  |  |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 140 |  | 70 |  | 99.8 |  |  |  |  |  |  |
International |  | 16 |  | 2 |  | * |  |  |  |  |  |
Worldwide |  | 157 |  | 72 |  | * |  |  |  |  |  |
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,464 |  | 1,191 |  | 22.9 |  |  |  |  |  |  |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
International |  | 1,228 |  | 1,072 |  | 14.5 |  |  |  |  |  |  |
Worldwide |  | 2,692 |  | 2,264 |  | 18.9 |  |  |  |  |  |  |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 285 |  | 249 |  | 14.1 |  |  |  |  |  |  |
International |  | 404 |  | 293 |  | 38.0 |  |  |  |  |  |  |
Worldwide |  | 689 |  | 542 |  | 27.0 |  |  |  |  |  |  |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 265 |  | 270 |  | (1.5) |  |  |  |  |  |  |
International |  | 518 |  | 557 |  | (7.0) |  |  |  |  |  |  |
Worldwide |  | 784 |  | 827 |  | (5.2) |  |  |  |  |  |  |
TECVAYLI(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 101 |  | 57 |  | 76.7 |  |  |  |  |  |  |
International |  | 33 |  | 6 |  | * |  |  |  |  |  |
Worldwide |  | 133 |  | 63 |  | * |  |  |  |  |  |
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9 |  | 16 |  | (41.3) |  |  |  |  |  |  |
International |  | 172 |  | 229 |  | (24.8) |  |  |  |  |  |  |
Worldwide |  | 181 |  | 245 |  | (25.9) |  |  |  |  |  |  |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 119 |  | 35 |  | * |  |  |  |  |  |
International |  | 60 |  | 64 |  | (6.1) |  |  |  |  |  |  |
Worldwide |  | 178 |  | 99 |  | 80.2 |  |  |  |  |  |  |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 766 |  | 600 |  | 27.5 |  |  |  |  |  |  |
International |  | 283 |  | 272 |  | 4.1 |  |  |  |  |  |  |
Worldwide |  | 1,049 |  | 872 |  | 20.2 |  |  |  |  |  |  |
OPSUMIT |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 356 |  | 273 |  | 30.4 |  |  |  |  |  |  |
International |  | 169 |  | 167 |  | 0.8 |  |  |  |  |  |  |
Worldwide |  | 524 |  | 440 |  | 19.1 |  |  |  |  |  |  |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 392 |  | 304 |  | 29.0 |  |  |  |  |  |  |
International |  | 76 |  | 58 |  | 30.7 |  |  |  |  |  |  |
Worldwide |  | 468 |  | 362 |  | 29.2 |  |  |  |  |  |  |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 18 |  | 23 |  | (24.6) |  |  |  |  |  |  |
International |  | 39 |  | 47 |  | (16.9) |  |  |  |  |  |  |
Worldwide |  | 56 |  | 70 |  | (19.5) |  |  |  |  |  |  |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 631 |  | 715 |  | (11.7) |  |  |  |  |  |  |
International |  | 197 |  | 212 |  | (7.0) |  |  |  |  |  |  |
Worldwide |  | 829 |  | 927 |  | (10.6) |  |  |  |  |  |  |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 518 |  | 578 |  | (10.4) |  |  |  |  |  |  |
International |  | — |  | — |  | — |  |  |  |  |  |  |
Worldwide |  | 518 |  | 578 |  | (10.4) |  |  |  |  |  |  |
OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 114 |  | 137 |  | (17.1) |  |  |  |  |  |  |
International |  | 197 |  | 212 |  | (7.0) |  |  |  |  |  |  |
Worldwide |  | 311 |  | 349 |  | (11.0) |  |  |  |  |  |  |
TOTAL INNOVATIVE MEDICINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 7,612 |  | 7,023 |  | 8.4 |  |  |  |  |  |  |
International |  | 5,950 |  | 6,390 |  | (6.9) |  |  |  |  |  |  |
Worldwide |  | 13,562 |  | 13,413 |  | 1.1 |  |  |  |  |  |  |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Cardiovascular(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,025 |  | 863 |  | 18.8 |  |  |  |  |  |  |
International |  | 781 |  | 640 |  | 22.1 |  |  |  |  |  |  |
Worldwide |  | 1,806 |  | 1,503 |  | 20.2 |  |  |  |  |  |  |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 692 |  | 571 |  | 21.3 |  |  |  |  |  |  |
International |  | 652 |  | 522 |  | 24.9 |  |  |  |  |  |  |
Worldwide |  | 1,344 |  | 1,092 |  | 23.0 |  |  |  |  |  |  |
ABIOMED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 303 |  | 264 |  | 15.0 |  |  |  |  |  |  |
International |  | 67 |  | 60 |  | 12.4 |  |  |  |  |  |  |
Worldwide |  | 371 |  | 324 |  | 14.5 |  |  |  |  |  |  |
OTHER CARDIOVASCULAR(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 30 |  | 28 |  | 3.3 |  |  |  |  |  |  |
International |  | 62 |  | 58 |  | 6.9 |  |  |  |  |  |  |
Worldwide |  | 92 |  | 87 |  | 5.7 |  |  |  |  |  |  |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,448 |  | 1,363 |  | 6.2 |  |  |  |  |  |  |
International |  | 892 |  | 881 |  | 1.3 |  |  |  |  |  |  |
Worldwide |  | 2,340 |  | 2,245 |  | 4.3 |  |  |  |  |  |  |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 270 |  | 241 |  | 12.1 |  |  |  |  |  |  |
International |  | 152 |  | 149 |  | 1.7 |  |  |  |  |  |  |
Worldwide |  | 422 |  | 390 |  | 8.1 |  |  |  |  |  |  |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 242 |  | 226 |  | 6.9 |  |  |  |  |  |  |
International |  | 160 |  | 142 |  | 12.3 |  |  |  |  |  |  |
Worldwide |  | 401 |  | 368 |  | 9.0 |  |  |  |  |  |  |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 504 |  | 491 |  | 2.8 |  |  |  |  |  |  |
International |  | 261 |  | 267 |  | (2.3) |  |  |  |  |  |  |
Worldwide |  | 765 |  | 757 |  | 1.0 |  |  |  |  |  |  |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 432 |  | 406 |  | 6.5 |  |  |  |  |  |  |
International |  | 320 |  | 323 |  | (0.9) |  |  |  |  |  |  |
Worldwide |  | 752 |  | 729 |  | 3.2 |  |  |  |  |  |  |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 987 |  | 975 |  | 1.2 |  |  |  |  |  |  |
International |  | 1,429 |  | 1,459 |  | (2.0) |  |  |  |  |  |  |
Worldwide |  | 2,416 |  | 2,434 |  | (0.7) |  |  |  |  |  |  |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 446 |  | 444 |  | 0.2 |  |  |  |  |  |  |
International |  | 641 |  | 673 |  | (4.7) |  |  |  |  |  |  |
Worldwide |  | 1,087 |  | 1,118 |  | (2.8) |  |  |  |  |  |  |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 542 |  | 531 |  | 2.1 |  |  |  |  |  |  |
International |  | 788 |  | 785 |  | 0.3 |  |  |  |  |  |  |
Worldwide |  | 1,330 |  | 1,316 |  | 1.0 |  |  |  |  |  |  |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 547 |  | 558 |  | (1.8) |  |  |  |  |  |  |
International |  | 710 |  | 743 |  | (4.4) |  |  |  |  |  |  |
Worldwide |  | 1,258 |  | 1,300 |  | (3.3) |  |  |  |  |  |  |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 438 |  | 444 |  | (1.4) |  |  |  |  |  |  |
International |  | 472 |  | 509 |  | (7.4) |  |  |  |  |  |  |
Worldwide |  | 910 |  | 953 |  | (4.6) |  |  |  |  |  |  |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 110 |  | 114 |  | (3.7) |  |  |  |  |  |  |
International |  | 238 |  | 233 |  | 2.2 |  |  |  |  |  |  |
Worldwide |  | 348 |  | 347 |  | 0.3 |  |  |  |  |  |  |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 4,008 |  | 3,759 |  | 6.6 |  |  |  |  |  |  |
International |  | 3,813 |  | 3,722 |  | 2.4 |  |  |  |  |  |  |
Worldwide |  | 7,821 |  | 7,481 |  | 4.5 |  |  |  |  |  |  |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 11,620 |  | 10,782 |  | 7.8 |  |  |  |  |  |  |
International |  | 9,763 |  | 10,112 |  | (3.4) |  |  |  |  |  |  |
Worldwide |  | $21,383 |  | 20,894 |  | 2.3 | % |  |  |  |  |  |
* Percentage greater than 100% or not meaningful (1)Previously included in Other Oncology (2) Previously referred to as Interventional Solutions
Operating Profit by Segment of Business |
|  | Fiscal First Quarter Ended |  |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |  |  |  |  |  |
Innovative Medicine(1) |  | $4,969 |  | 4,402 |  | 12.9 | % |  |  |  |  |  |  |  |  |  |  |
MedTech(2) |  | 1,520 |  | 1,409 |  | 7.9 |  |  |  |  |  |  |  |  |  |  |  |
Segment earnings before provision for taxes |  | 6,489 |  | 5,811 |  | 11.7 |  |  |  |  |  |  |  |  |  |  |  |
Less: Expense not allocated to segments (3) |  | 2,775 |  | 7,098 |  |  |  |  |  |  |  |  |  |  |  |  |
Worldwide income (loss) before tax |  | $3,714 |  | (1,287) |  |  |  |  |  |  |  |  |  |  |  |  |
(1) Innovative Medicine includes: •Intangible amortization expense of $0.7 billion in both the fiscal first quarter of 2024 and 2023. •One-time COVID-19 Vaccine related exit costs of $0.4 billion in the fiscal first quarter of 2023. •A restructuring related charge of $0.1 billion in both the fiscal first quarter of 2024 and 2023. (2) MedTech includes: •Intangible amortization expense of $0.4 billion in both the fiscal first quarter of 2024 and 2023. (3) Amounts not allocated to segments include interest (income)/expense and general corporate (income)/expense. The fiscal first quarters of 2024 and 2023 include charges for talc matters of $2.7 billion and $6.9 billion, respectively (See Note 11, Legal Proceedings, for additional details).
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas |
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | March 31, 2024 |  | April 2, 2023 |  | Percent Change |  |  |  |  |  |
United States |  | $11,620 |  | 10,782 |  | 7.8 | % |  |  |  |  |  |
Europe |  | 5,163 |  | 5,590 |  | (7.6) |  |  |  |  |  |  |
Western Hemisphere, excluding U.S. |  | 1,194 |  | 1,076 |  | 11.0 |  |  |  |  |  |  |
Asia-Pacific, Africa |  | 3,406 |  | 3,446 |  | (1.1) |  |  |  |  |  |  |
Total |  | $21,383 |  | 20,894 |  | 2.3 | % |  |  |  |  |  |

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration